Yousif Capital Management LLC Sells 1,261 Shares of Zoetis Inc. $ZTS

Yousif Capital Management LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,439 shares of the company’s stock after selling 1,261 shares during the quarter. Yousif Capital Management LLC’s holdings in Zoetis were worth $10,205,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter worth $25,000. 1248 Management LLC purchased a new stake in Zoetis in the first quarter worth $27,000. Saudi Central Bank purchased a new stake in Zoetis in the first quarter worth $29,000. REAP Financial Group LLC grew its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC grew its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.8%

NYSE ZTS opened at $142.29 on Tuesday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The stock has a market cap of $63.06 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.26 and a beta of 0.90. The stock’s fifty day moving average price is $149.04 and its 200-day moving average price is $154.19. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the firm posted $1.56 earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.